Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.56 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.56 |
| ▸ | PNMT | P11086 | 2/20 | 0.54 |
| ▸ | FAP | Q12884 | 1/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.49 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.49 |
| ▸ | KMO | O15229 | 2/20 | 0.46 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.42 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2029896 | 1.00 | DPP4 (0.56) | DPP4DPP7PNMTFAPDPP8 | |
| SCHEMBL29478411 | 1.00 | DPP4 (0.56) | DPP4DPP7PNMTFAPDPP8 | |
| SCHEMBL29478406 | 1.00 | DPP4 (0.56) | DPP4DPP7PNMTFAPDPP8 | |
| SCHEMBL2035161 | 1.00 | DPP4 (0.56) | DPP4DPP7PNMTFAPDPP8 | |
| SCHEMBL8513415 | 0.84 | PNMT (0.51) | DPP4DPP7PNMTFAPDPP8 | |
| SCHEMBL3752627 | 0.81 | PNMT (0.53) | DPP4DPP7PNMTFAPDPP8 | |
| SCHEMBL4990340 | 0.81 | PNMT (0.57) | DPP4DPP7PNMTKMOFFAR1 | |
| SCHEMBL2031957 | 0.81 | SLC6A4 (0.64) | DPP4DPP7ANPEPENPEPMEN1 | |
| SCHEMBL2033002 | 0.81 | SLC6A4 (0.64) | DPP4DPP7ANPEPENPEPMEN1 | |
| SCHEMBL288206 | 0.81 | SLC6A4 (0.64) | DPP4DPP7ANPEPENPEPMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250229081-A1 | NANOMATERIAL COATED ELECTRODE AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT | 2025-07-17 | — | — | US | disclosed |
| EP-4578868-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | FUJIFILM Corporation (JP) | 2025-07-02 | — | — | EP | disclosed |
| EP-4578867-A1 | CYCLIC PEPTIDE OR SALT THEREOF AND MDMX INHIBITOR | FUJIFILM Corporation (JP) | 2025-07-02 | — | — | EP | disclosed |
| US-20250179119-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | FUJIFILM CORPORATION (JP) | 2025-06-05 | — | — | US | disclosed |
| US-20250179120-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | FUJIFILM CORPORATION (JP) | 2025-06-05 | — | — | US | disclosed |
| US-20250084410-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF | Synthorx, Inc. (US) | 2025-03-13 | — | — | US | disclosed |
| US-12214043-B2 | Therapeutic nanomaterials | UNIVERSITY OF CONNECTICUT | 2025-02-04 | — | — | US | disclosed |
| US-12173291-B2 | Unnatural base pair compositions and methods of use | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-12-24 | — | — | US | disclosed |
| US-12102648-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2024-10-01 | — | — | US | disclosed |
| US-20240294962-A1 | REAGENTS AND METHODS FOR REPLICATION, TRANSCRIPTION, AND TRANSLATION IN SEMI-SYNTHETIC ORGANISMS | THE SCRIPPS RESEARCH INSTITUTE | 2024-09-05 | — | — | US | disclosed |
| US-20130274205-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130266597-A1 | Small Cationic Antimicrobial Peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-10-10 | — | — | US | disclosed |
| US-20130210745-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130123169-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8343475-B2 | Small cationic antimicrobial peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-01-01 | — | — | US | disclosed |
| US-20110236429-A1 | Small Cationic Antimicrobial Peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-09-29 | — | — | US | disclosed |
| US-20110150917-A1 | Small Cationic Antimicrobial Peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-06-23 | — | — | US | disclosed |
| EP-2061886-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | The University of British Columbia (CA) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008151434-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008022444-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179119-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | MLX, BMX, ADM2 | DPP4 1217/4885DPP7 481/4885PNMT 4699/4885 |
| US-20250179120-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | MDN1, MLX, BMX | DPP4 1374/4885DPP7 453/4885PNMT 4688/4885 |
| US-12173291-B2 | Unnatural base pair compositions and methods of use | RNGTT, SPOUT1, NPEPPS | DPP4 2157/4885DPP7 772/4885PNMT 1189/4885 |
| US-12102648-B2 | Orally-bioavailable nucleoside analogs | SLC29A2, SLC29A1, PNP | DPP4 93/4885DPP7 127/4885PNMT 1783/4885 |
| US-20250084410-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF | RNGTT, TRMT1, OSGEP | DPP4 2835/4885DPP7 1615/4885PNMT 1501/4885 |
| US-20130123169-A1 | PEPTIDOMIMETIC MACROCYCLES | GHRHR, GHSR, GHITM | DPP4 265/4885DPP7 232/4885PNMT 3742/4885 |
| US-12214043-B2 | Therapeutic nanomaterials | TIE1, TEKT1, POLRMT | DPP4 1357/4885DPP7 865/4885PNMT 788/4885 |
| US-20130210745-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | IL33, TPR, CDC37 | DPP4 677/4885DPP7 694/4885PNMT 1142/4885 |
| US-20240294962-A1 | REAGENTS AND METHODS FOR REPLICATION, TRANSCRIPTION, AND TRANSLATION IN SEMI-SYNTHETIC ORGANISMS | RNGTT, MAX, POLRMT | DPP4 2643/4885DPP7 1961/4885PNMT 765/4885 |
| US-20130274205-A1 | PEPTIDOMIMETIC MACROCYCLES | PROKR1, GLP1R, PROKR2 | DPP4 128/4885DPP7 50/4885PNMT 2237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.